Search Results
May 04, 2026, 19:01 ET Guesty and Alloggio announce strategic partnership to power full portfolio migration across ANZ
Booking.com, Expedia, Tripadvisor, Hopper, Google Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Funds, MSD Partners, Sixth Street Growth, Viola Growth, Flashpoint, and Vertex Ventures, Guesty's global team of 800+ employees across 16 offices is building the
More news about: Guesty
May 04, 2026, 19:01 ET Guesty and Alloggio announce strategic partnership to power full portfolio migration across ANZ
Booking.com, Expedia, Tripadvisor, Hopper, Google Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Funds, MSD Partners, Sixth Street Growth, Viola Growth, Flashpoint, and Vertex Ventures, Guesty's global team of 800+ employees across 16 offices is building the
More news about: Guesty
May 01, 2026, 07:00 ET Terex Reports First Quarter 2026 Results
$1,691MSDMaterials Processing8
More news about: Terex Corporation
Apr 23, 2026, 09:00 ET Survey Shows More Than 3 in 5 Americans Use AI Tools for Medical Information, but Most Take Steps to Check Sources and Information
95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest.About The Merck Manuals and MSD ManualsFirst published in 1899 as a pocket-sized reference for physicians and pharmacists, The Merck Manual has evolved into one of the world's
More news about: The Merck Manuals
Apr 23, 2026, 02:34 ET DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS
NCIS, was made possible with the philanthropic support of the Pangestu Family Foundation Gynaecological Cancer Research Fund, and contribution from MSD. The Pangestu Family Foundation shared, "We are proud to support the LARA trial because patients with rare and aggressive clear cell cancers urgently
More news about: National University Cancer Institute, Singapore (NCIS)
Apr 22, 2026, 09:36 ET MSD Lawyers Los Angeles Employment & Personal Injury Firm Hires Mark Russ as Trial Counsel
MSD Lawyers Appoints Veteran Trial Attorney Mark Russ as Trial Counsel, Bolstering Los Angeles Employment and Litigation Practice.LOS ANGELES, April 22, 2026 /PRNewswire/ -- MSD Lawyers (Mills Sadat Dowlat) has named
More news about: MSD Lawyers
Apr 22, 2026, 09:00 ET Phanes Therapeutics to Present Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab.Phanes is conducting clinical trials with spevatamig in multiple
More news about: Phanes Therapeutics, Inc.
Apr 22, 2026, 08:00 ET Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
LAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled
More news about: Google Cloud
Apr 22, 2026, 05:00 ET Guesty Launches ReplyAI Autopilot and AI Task Creation to Power Proactive Operations Inside the PMS
Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Fund, Inovia Capital, DFO Management (formerly MSD Capital), Sixth Street Growth, Viola Growth, and Flashpoint, Guesty's global team is building the future of the short-term rental industry under one
More news about: Guesty
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About A400/EP0031A400/EP0031
More news about: Kelun-Biotech
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).Astellas Cautionary NotesIn this press release, statements made with respect to current
More news about: Astellas Pharma Inc.
Apr 15, 2026, 09:00 ET Forward Networks Recognized for Eliminating Manual Security Investigations with Conversational AI
transformation. Founded in 2013 by four Stanford Ph.D.s, Forward Networks is headquartered in Santa Clara, California, and backed by leading investors including MSD Partners, Goldman Sachs, Andreessen Horowitz, Threshold Ventures, Section 32, Omega Venture Partners, and A. Capital. For more information, visit
More news about: Forward Networks, Inc.
Apr 14, 2026, 10:46 ET ASSAY RESULTS REPORT HIGH GRADE GOLD ENCOUNTERED IN COCA COLA ZONE TRENCHING PROGRAM AT WILDHORSE PROJECT; PHASE 1 DRILLING BEGINS
which will follow the trend to the east of the trenches.Wildhorse Drill Program CommencesMidnight Sun Drilling Inc. ("MSD") mobilized to the property late last week and reverse circulation drilling began over the weekend. Six (6) drill sites were permitted for the Coca
More news about: Glenstar Minerals Inc
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
9 registrational clinical studies in China. MSD is evaluating 17 ongoing Phase III global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Kelun-Biotech
Apr 09, 2026, 06:20 ET Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
continues to expand its global footprint through collaborations with world leading partners, including MSD and Crescent Biopharma, steadily advancing the global development of relevant assets. Notably, MSD has evaluated 17 global Phase III clinical trials for sacituzumab tirumotecan (sac-TMT, 佳泰莱®),
More news about: Kelun-Biotech
Apr 07, 2026, 15:05 ET Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.Phanes is conducting clinical trials
More news about: Phanes Therapeutics
Apr 07, 2026, 09:23 ET Cancer and Careers Announces Inaugural Index of Best Companies for Working with Cancer
GroupMarriott InternationalMaven PartnershipMemorial Sloan Kettering Cancer CenterMerck, known as MSD outside of the U.S. and CanadaNestléPfizer, Inc.Publicis GroupeRenault GroupSanofiStellantis"For
More news about: Cancer and Careers
Apr 06, 2026, 10:00 ET NSC Study Highlights Benefits of Workplace Injury Prevention Technology
Perceptions of MSD Prevention Technology, draws on an MSD Solutions Lab survey of more than 400 non-managerial workers across diverse industries – including manufacturing, construction, health care and transportation and warehousing – and found that nearly 70% experience job-related MSD symptoms.
More news about: National Safety Council
Apr 01, 2026, 13:29 ET GLENSTAR RECEIVES APPROVAL FOR EXTENSIVE DRILL PROGRAM AT WILDHORSE TUNGSTEN-COPPER-POLYMETALLIC PROJECT IN NEVADA
the exploration areas and planned drill target sites.The Company has also contracted Midnight Sun Drilling Inc. ("MSD") to conduct the drill program at Wildhorse. MSD is a well-established drilling company in business for over 50 years, with offices in the Yukon, Alaska, and Nevada that
More news about: Glenstar Minerals Inc
Mar 30, 2026, 10:00 ET Scott+Scott Attorneys at Law LLP Announce a Notice of Proposed Class Action Settlement for the Hayward Holdings, Inc., Securities Litigation
ASSOCIATES III, L.P., CCMP CAPITAL ASSOCIATES III GP, LLC, CCMP CAPITAL, LP, CCMP CAPITAL GP, LLC, MSD AQUA PARTNERS, LLC, MSD PARTNERS, L.P., MSD PARTNERS (GP), LLC, MARK MCFADDEN, GREG BRENNEMAN, TIMOTHY WALSH, CHRISTOPHER BERTRAND, and
More news about: Scott+Scott Attorneys at Law LLP
Mar 26, 2026, 15:00 ET Ministério da Saúde, MSD e Instituto Butantan assinam Termo de Compromisso para produção local de tratamento inovador para pacientes oncológicos
aprovada pela referida Comissão.Sobre a MSD Por mais de 130 anos, a MSD cria invenções para a vida, trazendo ao mercado medicamentos inovadores para combater as doenças mais desafiadoras. MSD é o nome pelo qual é conhecida a Merck & Co. Inc. fora dos Estados
More news about: MSD Brasil
Mar 26, 2026, 08:00 ET Merck Manuals: What Parents Need to Know About Kawasaki Disease
MerckManuals.com.About The Merck Manuals and MSD ManualsFirst published in 1899 as a pocket-sized reference for physicians and pharmacists, The Merck Manual has evolved into one of the world's
More news about: The Merck Manuals
Mar 25, 2026, 09:00 ET Forward Networks Recognized for Advancing AI Through Digital Twin Technology
transformation. Founded in 2013 by four Stanford Ph.D.s, Forward Networks is headquartered in Santa Clara, California, and backed by leading investors including MSD Partners, Goldman Sachs, Andreessen Horowitz, Threshold Ventures, Section 32, Omega Venture Partners, and A. Capital. For more information, visit
More news about: Forward Networks, Inc.
Mar 23, 2026, 22:31 ET KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
better.Steady Advancement of Global Collaboration and Comprehensive Strength Authoritatively RecognizedCollaboration with MSD: As at the date of this announcement, MSD is evaluating initiated 17 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or
More news about: Kelun-biotech
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
Molecule Inhibitor)Data from the Phase Ib/II STAMINA study: Following the initiation of a global clinical collaboration with MSD, Antengene is evaluating ATG-037 in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients
More news about: Antengene Corporation Limited